Circulating levels of TNF receptor II are prognostic for patients with peripheral T-cell non-Hodgkin lymphoma

Clinical Cancer Research

Volumn 18, Issue 13, 2012, Pages 3637-3647

  Heemann, Christina ^a,b   Kreuz, Markus ^b,c   Stoller, Irene ^a   Schoof, Nils ^a,b,e   Von Bonin, Frederike ^a   Ziepert, Marita ^c   Lof̈fler, Markus ^c   Jung, Wolfram ^a   Pfreundschuh, Michael ^d   Trum̈per, Lorenz ^a,b   Kube, Dieter ^a,b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b Deutsche Forschungsgemeinschaft   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; INTERLEUKIN 10; INTERLEUKIN 4 RECEPTOR; THYMINE; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DNA DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EVENT FREE SURVIVAL; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IL 10 GENE; IL 4 GENE; INTERLEUKIN 10 BLOOD LEVEL; INTERLEUKIN 4 RECEPTOR BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TNFRI GENE; TNFRII GENE; TREATMENT RESPONSE; TUMOR NECROSIS FACTOR RECEPTOR 1 BLOOD LEVEL; TUMOR NECROSIS FACTOR RECEPTOR 2 BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; GENE FREQUENCY; HUMANS; INTERLEUKIN-10; KAPLAN-MEIER ESTIMATE; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RISK; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84863334213     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-3299     Document Type: Article

References (57)

1. Rudiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 2002;13:140-9. (Pubitemid 34436738)
2. Armitage JO, Vose JM, Weisenburger DD. Towards understanding the peripheral T-cell lymphomas. Ann Oncol 2004;15:1447-9. (Pubitemid 39409731)
3. Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J, Haioun C, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 1998;92:76-82. (Pubitemid 28303178)
4. Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010;116:3418-25.
5. Nickelsen M, Ziepert M, Zeynalova S, Glass B, Metzner B, Leithaeuser M, et al. High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Ann Oncol 2009;20:1977-84.
6. O'Leary HM, Savage KJ. Novel therapies in peripheral T-cell lymphomas. Curr Hematol Malig Rep 2008;3:213-20.
7. Reimer P, Rudiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009;27:106-13.
8. Ansell SM, Habermann TM, Kurtin PJ, Witzig TE, Chen MG, Li CY, et al. Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. J Clin Oncol 1997;15:2296-301. (Pubitemid 27251131)
9. Ballester B, Ramuz O, Gisselbrecht C, Doucet G, Loi L, Loriod B, et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene 2006;25:1560-70. (Pubitemid 43361941)
10. Escalon MP, Liu NS, Yang Y, Hess M, Walker PL, Smith TL, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 2005;103:2091-8. (Pubitemid 40605117)
11. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004;4:11-22. (Pubitemid 38111131)
12. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007;117:1175-83. (Pubitemid 46718402)
13. Voorzanger N, Touitou R, Garcia E, Delecluse HJ, Rousset F, Joab I, et al. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res 1996;56:5499-505. (Pubitemid 27011386)
14. Warzocha K, Salles G. The tumor necrosis factor signaling complex: choosing a path toward cell death or cell proliferation. Leuk Lymphoma 1998;29:81-92. (Pubitemid 28236542)
15. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003;3:745-56. (Pubitemid 41070815)
16. Oregon-Romero E, Vazquez-Del Mercado M, Navarro-Hernandez RE, Torres-Carrillo N, Martinez-Bonilla G, Estrada-Garcia I, et al. Tumor necrosis factor receptor 2 M196R polymorphism in rheumatoid arthritis and osteoarthritis: relationship with sTNFR2 levels and clinical features. Rheumatol Int 2006;27:53-9. (Pubitemid 44655749)
17. Wang SS, Cerhan JR, Hartge P, Davis S, Cozen W, Severson RK, et al. Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res 2006;66:9771-80. (Pubitemid 44623679)
18. Warzocha K, Salles G, Bienvenu J, Barbier Y, Bastion Y, Doche C, et al. Prognostic significance of TNF alpha and its p55 soluble receptor in malignant lymphomas. Leukemia 1997;11 Suppl 3:441-3.
19. Warzocha K, Ribeiro P, Bienvenu J, Roy P, Charlot C, Rigal D, et al. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood 1998;91:3574-81. (Pubitemid 28225722)
20. Warzocha K, Salles G, Bienvenu J, Bastion Y, Dumontet C, Renard N, et al. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. J Clin Oncol 1997;15:499-508. (Pubitemid 27074216)
21. Gupta R, Sharma SC, Das SN. Association of TNF-alpha and TNFR1 promoters and 30 UTR region of TNFR2 gene polymorphisms with genetic susceptibility to tobacco-related oral carcinoma in Asian Indians. Oral Oncol 2008;44:455-63.
22. Constantin A, Dieude P, Lauwers-Cances V, Jamard B, Mazieres B, Cambon-Thomsen A, et al. Tumor necrosis factor receptor II gene polymorphism and severity of rheumatoid arthritis. Arthritis Rheum 2004;50:742-7. (Pubitemid 38326173)
23. Mestiri S, Bouaouina N, Ben Ahmed S, Chouchane L. A functional polymorphism of the tumor necrosis factor receptor-II gene associated with the survival and relapse prediction of breast carcinoma. Cytokine 2005;30:182-7. (Pubitemid 40615966)
24. Goto N, Tsurumi H, Takemura M, Hara T, Sawada M, Kasahara S, et al. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma. Eur J Haematol 2006;77:217-25. (Pubitemid 44181384)
25. Metkar SS, Naresh KN, Manna PP, Srinivas V, Advani SH, Nadkarni JJ. Circulating levels of TNF alpha and TNF receptor superfamily members in lymphoid neoplasia. Am J Hematol 2000;65:105-10.
26. Warzocha K, Bienvenu J, Ribeiro P, Moullet I, Dumontet C, Neidhardt-Berard EM, et al. Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients. Br J Cancer 1998;77:2357-62. (Pubitemid 28263966)
27. Blay JY, Burdin N, Rousset F, Lenoir G, Biron P, Philip T, et al. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood 1993;82:2169-74. (Pubitemid 23294002)
28. Cortes J, Kurzrock R. Interleukin-10 in non-Hodgkin's lymphoma. Leuk Lymphoma 1997;26:251-9. (Pubitemid 27401908)
29. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683-765. (Pubitemid 32368050)
30. Howell WM, Rose-Zerilli MJ. Interleukin-10 polymorphisms, cancer susceptibility and prognosis. Fam Cancer 2006;5:143-9. (Pubitemid 43824470)
31. Cervenak L, Morbidelli L, Donati D, Donnini S, Kambayashi T, Wilson JL, et al. Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10. Blood 2000;96:2568-73.
32. Erdman SE, Rao VP, Poutahidis T, Ihrig MM,GeZ, Feng Y, et al. CD4(+) CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Res 2003;63:6042-50. (Pubitemid 37187508)
33. Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 2005;78:1043-51. (Pubitemid 41572467)
34. Hohaus S, Giachelia M, Massini G, Vannata B, Criscuolo M, Martini M, et al. Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. Leuk Res 2009;33:1352-6.
35. Lech-Maranda E, Bienvenu J, Michallet AS, Houot R, Robak T, Coiffier B, et al. Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. Eur Cytokine Netw 2006;17:60-6.
36. Cunningham LM, Chapman C, Dunstan R, Bell MC, Joske DJ. Polymorphisms in the interleukin 10 gene promoter are associated with susceptibility to aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44:251-5.
37. Berglund M, Thunberg U, Roos G, Rosenquist R, Enblad G. The interleukin-10 gene promoter polymorphism (-1082) does not correlate with clinical outcome in diffuse large B-cell lymphoma. Blood 2005;105:4894-5; author reply 4895.
38. Kube D, Hua TD, Kloss M, Kulle B, Brockmoller J, Wojnowski L, et al. The interleukin-10 gene promoter polymorphism -1087AG does not correlate with clinical outcome in non-Hodgkin's lymphoma. Genes Immun 2007;8:164-7. (Pubitemid 46390915)
39. Lech-Maranda E, Baseggio L, Bienvenu J, Charlot C, Berger F, Rigal D, et al. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 2004;103:3529-34. (Pubitemid 38525688)
40. Boulland ML, Meignin V, Leroy-Viard K, Copie-Bergman C, Briere J, Touitou R, et al. Human interleukin-10 expression in T/natural killer-cell lymphomas: association with anaplastic large cell lymphomas and nasal natural killer-cell lymphomas. Am J Pathol 1998;153:1229-37. (Pubitemid 28465846)
41. Ho IC, Kim JI, Szabo SJ, Glimcher LH. Tissue-specific regulation of cytokine gene expression. Cold Spring Harb Symp Quant Biol 1999;64:573-84. (Pubitemid 30329323)
42. Gravisaco MJ, Mongini C, Alvarez E, Ruybal P, Escalada A, Sanchez-Lockhart M, et al. IL-2, IL-10, IL-15 and TNF are key regulators of murine T-cell lymphoma growth. Int J Mol Med 2003;12:627-32.
43. Lee JJ, Kim DH, Lee NY, Sohn SK, KimJG, Kim HJ, et al. Interleukin-10 gene polymorphism influences the prognosis of T-cell non-Hodgkin lymphomas. Br J Haematol 2007;137:329-36. (Pubitemid 46650250)
44. Kube D, Hua TD, von Bonin F, Schoof N, Zeynalova S, Kloss M, et al. Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study. Clin Cancer Res 2008;14:3777-84.
45. Schoof N, von Bonin F, Zeynalova S, Ziepert M, Jung W, Loeffler M, et al. Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trial. Ann Oncol 2009;20:1548-54.
46. Hackstein H, Hecker M, Kruse S, Bohnert A, Ober C, Deichmann KA, et al. A novel polymorphism in the 50 promoter region of the human interleukin-4 receptor alpha-chain gene is associated with decreased soluble interleukin-4 receptor protein levels. Immunogenetics 2001;53:264-9. (Pubitemid 32678760)
47. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634-41. (Pubitemid 38970554)
48. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rudolph C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004;104:626-33. (Pubitemid 38970553)
49. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105-16.
50. Kube D, Mormann M, Tomiuk J, Rieth H, Hua TD, Kremsner PG, et al. Simultaneous analysis of interleukin-10 gene microsatellites and single-nucleotide polymorphisms in parallel with tumour necrosis factor and interferon-gamma short tandem repeats by fluorescence-based polymerase chain reaction. Genes Immun 2003;4:459-68. (Pubitemid 38967612)
51. Mormann M, Rieth H, Hua TD, Assohou C, Roupelieva M, Hu SL, et al. Mosaics of gene variations in the Interleukin-10 gene promoter affect interleukin-10 production depending on the stimulation used. Genes Immun 2004;5:246-55. (Pubitemid 38961156)
52. Skibola CF, Curry JD, Nieters A. Genetic susceptibility to lymphoma. Haematologica 2007;92:960-9. (Pubitemid 350144243)
53. Habermann TM, Wang SS, Maurer MJ, Morton LM, Lynch CF, Ansell SM, et al. Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. Blood 2008;112:2694-702.
54. Lee EB, Jeon HS, Yoo SS, Choi YY, Kang HG, Cho S, et al. Polymorphisms in apoptosis-related genes and survival of patients with early-stage non-small-cell lung cancer. Ann Surg Oncol 2010;17:2608-18.
55. Kim S, Moon SM, Kim YS, Kim JJ, Ryu HJ, Kim YJ, et al. TNFR1 promoter -329G/T polymorphism results in allele-specific repression of TNFR1 expression. Biochem Biophys Res Commun 2008;368:395-401.
56. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009;9:361-71.
57. Aderka D, Sorkine P, Abu-Abid S, Lev D, Setton A, Cope AP, et al. Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNFleaking during isolated limb perfusion. Relevance to the pathophysiology of septic shock. J Clin Invest 1998;101:650-9. (Pubitemid 28084249)